Items Tagged ‘Femara’

October 28th, 2015

The Type of Breast Cancer Determines Effectiveness of Different Hormonal Therapies


According to the results of a recent study published in the Journal of Clinical Oncology, women with certain subtypes of hormone-positive breast cancer appear to benefit differently when treated with hormone therapy. Hormone-positive breast cancer refers to breast cancer that is stimulated to grow from the female hormone, estrogen. Therefore, a standard treatment component for […]

View full entry

Tags: AI, anti-estrogen agent, aromatase inhibitors, Breast Cancer, Femara, hormone-positive breast cancer, IDC, ILC, letrozole, News, tamoxifen

February 27th, 2015

Palbociclib/Letrozole Improves Outcomes of Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer


The results of the phase II PALOMA-1/TRIO-18 trial were recently reported in The Lancet Oncology and suggest that the addition of Ibrance® (palbociclib) to Femara® (letrozole) delayed the time to cancer progression when used as first-line treatment for advanced breast cancer in postmenopausal women with estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)-negative disease. […]

View full entry

Tags: Breast Cancer, ER-positive, estrogen receptor-positive, Femara, HER-2 negative, human epidermal growth factor receptor-negative, Ibrance, kinase inhibitor, letrozole, Metastatic Breast Cancer, News, palbociclib